Illustrative image.

Saxenda

Name: Saxenda
Brand: NovoNordisk
Availability: InStock

Liraglutide

Prescription required

$1200.00

6mg/mL · 3 × 5 pen · 3 months supply

BrandBranded medicine· By NovoNordisk

$400.00 per month

How long a supply?

1 month$400.00 a monthOne-off$400.00

3 months$400.00 a monthOne-off$1200.00

6 months$400.00 a monthOne-off$2400.00

Supplied from Israel

Test mode: no payment is taken. View cart

Ships cold, in insulated packing

This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.

Annual cost

$4800a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

FDA boxed warningRisk of thyroid c-cell tumors

Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether SAXENDA causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.

SAXENDA is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of SAXENDA and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with SAXENDA.

Liraglutide causes thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether SAXENDA causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.

SAXENDA is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and the symptoms of thyroid tumors.

Read this with the rest of the clinical information

About Saxenda

Overview

Saxenda contains liraglutide, a GLP-1 receptor agonist supplied in a prefilled injection pen. It is used with a reduced-calorie diet and increased physical activity to reduce excess weight and maintain weight loss long term in adults and children aged 12 years and older who have obesity and weigh more than 60 kg. It is also used in adults with overweight and at least one weight-related health condition. Liraglutide activates GLP-1 receptors, which are involved in regulating appetite and calorie intake.

What it treats

Used with a reduced-calorie diet and increased physical activity to reduce excess weight and maintain weight loss long term in: • Adults and children aged 12 years and older with obesity who weigh more than 60 kg. • Adults with overweight and at least one weight-related health condition.

Safety information

Side effects

Common side effects include nausea, diarrhea, constipation, vomiting, injection-site reactions, headache, low blood sugar, indigestion, tiredness, dizziness, abdominal pain, upper abdominal pain, fever, gastroenteritis (stomach and intestinal inflammation), and increased blood levels of lipase, a digestive enzyme. Serious risks include inflammation of the pancreas, gallbladder disease, low blood sugar, increased heart rate, sudden kidney injury due to fluid loss, severe stomach or intestinal problems, serious allergic reactions, and thyroid C-cell tumors. Contact a doctor promptly if a serious reaction is suspected. Stop Saxenda if pancreatitis is suspected. If a serious allergic reaction occurs, including anaphylaxis or angioedema (swelling beneath the skin), stop Saxenda and seek medical help immediately. In adults, low blood sugar can occur when Saxenda is used with insulin or medicines that increase insulin release, such as sulfonylureas. Low blood sugar has also occurred in children taking Saxenda without type 2 diabetes. Heart rate should be monitored regularly, and kidney function should be checked when side effects could cause fluid loss. Saxenda is not recommended for people with severely delayed stomach emptying (gastroparesis). Stomach contents entering the lungs during general anesthesia or deep sedation has been reported with this class of medicine. Tell your healthcare providers about Saxenda use before any planned surgery or procedure.

FDA boxed warning

Risk of thyroid c-cell tumors

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Seek immediate medical attention for a lump in your neck, difficulty swallowing or breathing, or hoarseness that does not go away. - Seek immediate medical attention for severe stomach pain, severe vomiting or severe diarrhea.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Do not use Saxenda if you or a family member has had medullary thyroid carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use it if you have had a serious allergic reaction to liraglutide or any of its other ingredients. Saxenda may harm an unborn baby. Stop using it if pregnancy is recognised. It is not recommended for people with severe gastroparesis (severely delayed stomach emptying). Conditions requiring caution include inflammation of the pancreas, gallbladder disease, low blood sugar, an increased heart rate, severe digestive side effects and dehydration that may lead to acute kidney injury. Stop Saxenda if pancreatitis is suspected. Suspected gallstones or gallbladder inflammation require investigation. Heart rate should be checked regularly, and kidney function should be monitored if side effects could cause dehydration. Low blood sugar can occur in adults taking Saxenda with insulin or medicines that stimulate insulin release, such as sulfonylureas. It has also occurred in children taking Saxenda without type 2 diabetes. If a serious allergic reaction occurs, stop Saxenda and seek medical advice promptly. Tell your healthcare team about any planned surgery or procedure: inhalation of stomach contents into the lungs has been reported during general anaesthesia or deep sedation in people receiving medicines in this class.

Interactions

Saxenda slows stomach emptying, which may affect how medicines taken by mouth are absorbed. Tell your doctor about any oral medicines you take, as these should be used with caution alongside Saxenda.

Using Saxenda

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store in the original carton to protect it from light. Check the pack for whether it must be refrigerated before first use and how long it may be kept at room temperature afterwards. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label SAXENDA (LIRAGLUTIDE) INJECTION, SOLUTION [NOVO NORDISK PHARMACEUTICAL INDUSTRIES, LP] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.